Baseline hepatitis B core antibody predicts treatment response in chronic hepatitis B patients receiving long‐term entecavir
Summary Studies regarding the clinical significance of quantitative hepatitis B core antibody (anti‐HBc) in patients with chronic hepatitis B receiving first‐line nucleos(t)ide analogues is limited. The aim of this study was to determine the performance of anti‐HBc as a predictor for hepatitis B e a...
Gespeichert in:
| Veröffentlicht in: | Journal of viral hepatitis 2017-02, Vol.24 (2), p.148-154 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 154 |
|---|---|
| container_issue | 2 |
| container_start_page | 148 |
| container_title | Journal of viral hepatitis |
| container_volume | 24 |
| creator | Xu, J.‐H. Song, L.‐W. Li, N. Wang, S. Zeng, Z. Si, C.‐W. Li, J. Mao, Q. Zhang, D.‐Z. Tang, H. Sheng, J.‐F. Chen, X.‐Y. Ning, Q. Shi, G.‐F. Xie, Q. Yuan, Q. Yu, Y.‐Y. Xia, N.‐S. |
| description | Summary
Studies regarding the clinical significance of quantitative hepatitis B core antibody (anti‐HBc) in patients with chronic hepatitis B receiving first‐line nucleos(t)ide analogues is limited. The aim of this study was to determine the performance of anti‐HBc as a predictor for hepatitis B e antigen (HBeAg) seroconversion in HBeAg‐positive CHB patients treated with entecavir. This was a retrospective cohort study consisting of 139 Chinese patients enrolled in a multicenter clinical trial treated with entecavir or entecavir maleate for up to 240 weeks. Anti‐HBc evaluation was conducted for all the available samples using a newly developed double‐sandwich anti‐HBc immunoassay. At week 240, 35 (25.2%) patients achieved a serological response (HBeAg seroconversion) and these patients at week 240 had significantly higher levels of anti‐HBc (P |
| doi_str_mv | 10.1111/jvh.12626 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1844355101</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1928256185</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3816-73a3cb3a144a25482a94e7658910fadb7d430cc54c17f4fffd334cfd5ec0820b3</originalsourceid><addsrcrecordid>eNp90U1rFDEYB_BQLLauHvoFSsCLPUyb15ns0Za-WApe1GvIZJ7pZplJxiS7spfiR_Az-kmadWtBQXPJA_nxJ8kfoSNKTmlZZ8v14pSymtV76JDyWlZMzfmL7SxZRSQRB-hVSktCKGeSvkQHrFFz2lB5iB7OTYLBecALmEx22SV8jm2IgI3Prg3dBk8ROmdzwjmCySP4jCOkKfgE2HlsFzF4Z_8I2E7FpQItuLXz93gI_v7n9x8Z4ojLEVizdvE12u_NkODN0z5Dn68uP13cVHcfrz9cvL-rLFe0rhpuuG25oUIYJoViZi6gqWV5BelN1zad4MRaKSxtetH3fce5sH0nwRLFSMtn6N0ud4rh6wpS1qNLFobBeAirpKkSgktJyw_N0Nu_6DKsoi-303TOFJM1VfK_SklVUymlKupkp2wMKUXo9RTdaOJGU6K31elSnf5VXbHHT4mrdoTuWf7uqoCzHfjmBtj8O0nffrnZRT4C_oCkpA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1858615558</pqid></control><display><type>article</type><title>Baseline hepatitis B core antibody predicts treatment response in chronic hepatitis B patients receiving long‐term entecavir</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Xu, J.‐H. ; Song, L.‐W. ; Li, N. ; Wang, S. ; Zeng, Z. ; Si, C.‐W. ; Li, J. ; Mao, Q. ; Zhang, D.‐Z. ; Tang, H. ; Sheng, J.‐F. ; Chen, X.‐Y. ; Ning, Q. ; Shi, G.‐F. ; Xie, Q. ; Yuan, Q. ; Yu, Y.‐Y. ; Xia, N.‐S.</creator><creatorcontrib>Xu, J.‐H. ; Song, L.‐W. ; Li, N. ; Wang, S. ; Zeng, Z. ; Si, C.‐W. ; Li, J. ; Mao, Q. ; Zhang, D.‐Z. ; Tang, H. ; Sheng, J.‐F. ; Chen, X.‐Y. ; Ning, Q. ; Shi, G.‐F. ; Xie, Q. ; Yuan, Q. ; Yu, Y.‐Y. ; Xia, N.‐S.</creatorcontrib><description>Summary
Studies regarding the clinical significance of quantitative hepatitis B core antibody (anti‐HBc) in patients with chronic hepatitis B receiving first‐line nucleos(t)ide analogues is limited. The aim of this study was to determine the performance of anti‐HBc as a predictor for hepatitis B e antigen (HBeAg) seroconversion in HBeAg‐positive CHB patients treated with entecavir. This was a retrospective cohort study consisting of 139 Chinese patients enrolled in a multicenter clinical trial treated with entecavir or entecavir maleate for up to 240 weeks. Anti‐HBc evaluation was conducted for all the available samples using a newly developed double‐sandwich anti‐HBc immunoassay. At week 240, 35 (25.2%) patients achieved a serological response (HBeAg seroconversion) and these patients at week 240 had significantly higher levels of anti‐HBc (P<.01). We defined 4.65 log10 IU·mL−1, with a maximum sum of sensitivity and specificity, as the optimal cut‐off value of baseline anti‐HBc level to predict seroconversion. Patients with baseline anti‐HBc ≥4.65 log10 IU·mL−1 had 28.0% (26/93) and 35.5% (33/93) chance of seroconversion at weeks 144 and 240, respectively. The baseline anti‐HBc level was the strongest predictor for seroconversion at week 144 (OR: 5.78, 95% confidence interval [CI]: 2.05‐16.34, P=.001). The baseline anti‐HBc level was a strong predictor for seroconversion at week 240 (OR: 5.36, 95% CI: 2.17‐13.25, P<.001). Hence, baseline anti‐HBc titre is a useful predictor of long‐term entecavir therapy efficacy in HBeAg‐positive CHB patients, which could be used to optimize antiviral therapy.</description><identifier>ISSN: 1352-0504</identifier><identifier>EISSN: 1365-2893</identifier><identifier>DOI: 10.1111/jvh.12626</identifier><identifier>PMID: 27891715</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Adult ; Antiviral agents ; Antiviral Agents - therapeutic use ; Antiviral drugs ; China ; entecavir ; Female ; Guanine - analogs & derivatives ; Guanine - therapeutic use ; Health risk assessment ; Hepatitis ; Hepatitis B Antibodies - blood ; hepatitis B core antibody ; Hepatitis B e antigen ; Hepatitis B e Antigens - blood ; Hepatitis B, Chronic - drug therapy ; Hepatitis B, Chronic - immunology ; Humans ; Interferon ; Male ; Patients ; Prognosis ; Retrospective Studies ; Seroconversion ; Treatment Outcome</subject><ispartof>Journal of viral hepatitis, 2017-02, Vol.24 (2), p.148-154</ispartof><rights>2016 John Wiley & Sons Ltd</rights><rights>2016 John Wiley & Sons Ltd.</rights><rights>Copyright © 2017 John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3816-73a3cb3a144a25482a94e7658910fadb7d430cc54c17f4fffd334cfd5ec0820b3</citedby><cites>FETCH-LOGICAL-c3816-73a3cb3a144a25482a94e7658910fadb7d430cc54c17f4fffd334cfd5ec0820b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fjvh.12626$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fjvh.12626$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27891715$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Xu, J.‐H.</creatorcontrib><creatorcontrib>Song, L.‐W.</creatorcontrib><creatorcontrib>Li, N.</creatorcontrib><creatorcontrib>Wang, S.</creatorcontrib><creatorcontrib>Zeng, Z.</creatorcontrib><creatorcontrib>Si, C.‐W.</creatorcontrib><creatorcontrib>Li, J.</creatorcontrib><creatorcontrib>Mao, Q.</creatorcontrib><creatorcontrib>Zhang, D.‐Z.</creatorcontrib><creatorcontrib>Tang, H.</creatorcontrib><creatorcontrib>Sheng, J.‐F.</creatorcontrib><creatorcontrib>Chen, X.‐Y.</creatorcontrib><creatorcontrib>Ning, Q.</creatorcontrib><creatorcontrib>Shi, G.‐F.</creatorcontrib><creatorcontrib>Xie, Q.</creatorcontrib><creatorcontrib>Yuan, Q.</creatorcontrib><creatorcontrib>Yu, Y.‐Y.</creatorcontrib><creatorcontrib>Xia, N.‐S.</creatorcontrib><title>Baseline hepatitis B core antibody predicts treatment response in chronic hepatitis B patients receiving long‐term entecavir</title><title>Journal of viral hepatitis</title><addtitle>J Viral Hepat</addtitle><description>Summary
Studies regarding the clinical significance of quantitative hepatitis B core antibody (anti‐HBc) in patients with chronic hepatitis B receiving first‐line nucleos(t)ide analogues is limited. The aim of this study was to determine the performance of anti‐HBc as a predictor for hepatitis B e antigen (HBeAg) seroconversion in HBeAg‐positive CHB patients treated with entecavir. This was a retrospective cohort study consisting of 139 Chinese patients enrolled in a multicenter clinical trial treated with entecavir or entecavir maleate for up to 240 weeks. Anti‐HBc evaluation was conducted for all the available samples using a newly developed double‐sandwich anti‐HBc immunoassay. At week 240, 35 (25.2%) patients achieved a serological response (HBeAg seroconversion) and these patients at week 240 had significantly higher levels of anti‐HBc (P<.01). We defined 4.65 log10 IU·mL−1, with a maximum sum of sensitivity and specificity, as the optimal cut‐off value of baseline anti‐HBc level to predict seroconversion. Patients with baseline anti‐HBc ≥4.65 log10 IU·mL−1 had 28.0% (26/93) and 35.5% (33/93) chance of seroconversion at weeks 144 and 240, respectively. The baseline anti‐HBc level was the strongest predictor for seroconversion at week 144 (OR: 5.78, 95% confidence interval [CI]: 2.05‐16.34, P=.001). The baseline anti‐HBc level was a strong predictor for seroconversion at week 240 (OR: 5.36, 95% CI: 2.17‐13.25, P<.001). Hence, baseline anti‐HBc titre is a useful predictor of long‐term entecavir therapy efficacy in HBeAg‐positive CHB patients, which could be used to optimize antiviral therapy.</description><subject>Adult</subject><subject>Antiviral agents</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Antiviral drugs</subject><subject>China</subject><subject>entecavir</subject><subject>Female</subject><subject>Guanine - analogs & derivatives</subject><subject>Guanine - therapeutic use</subject><subject>Health risk assessment</subject><subject>Hepatitis</subject><subject>Hepatitis B Antibodies - blood</subject><subject>hepatitis B core antibody</subject><subject>Hepatitis B e antigen</subject><subject>Hepatitis B e Antigens - blood</subject><subject>Hepatitis B, Chronic - drug therapy</subject><subject>Hepatitis B, Chronic - immunology</subject><subject>Humans</subject><subject>Interferon</subject><subject>Male</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>Seroconversion</subject><subject>Treatment Outcome</subject><issn>1352-0504</issn><issn>1365-2893</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp90U1rFDEYB_BQLLauHvoFSsCLPUyb15ns0Za-WApe1GvIZJ7pZplJxiS7spfiR_Az-kmadWtBQXPJA_nxJ8kfoSNKTmlZZ8v14pSymtV76JDyWlZMzfmL7SxZRSQRB-hVSktCKGeSvkQHrFFz2lB5iB7OTYLBecALmEx22SV8jm2IgI3Prg3dBk8ROmdzwjmCySP4jCOkKfgE2HlsFzF4Z_8I2E7FpQItuLXz93gI_v7n9x8Z4ojLEVizdvE12u_NkODN0z5Dn68uP13cVHcfrz9cvL-rLFe0rhpuuG25oUIYJoViZi6gqWV5BelN1zad4MRaKSxtetH3fce5sH0nwRLFSMtn6N0ud4rh6wpS1qNLFobBeAirpKkSgktJyw_N0Nu_6DKsoi-303TOFJM1VfK_SklVUymlKupkp2wMKUXo9RTdaOJGU6K31elSnf5VXbHHT4mrdoTuWf7uqoCzHfjmBtj8O0nffrnZRT4C_oCkpA</recordid><startdate>201702</startdate><enddate>201702</enddate><creator>Xu, J.‐H.</creator><creator>Song, L.‐W.</creator><creator>Li, N.</creator><creator>Wang, S.</creator><creator>Zeng, Z.</creator><creator>Si, C.‐W.</creator><creator>Li, J.</creator><creator>Mao, Q.</creator><creator>Zhang, D.‐Z.</creator><creator>Tang, H.</creator><creator>Sheng, J.‐F.</creator><creator>Chen, X.‐Y.</creator><creator>Ning, Q.</creator><creator>Shi, G.‐F.</creator><creator>Xie, Q.</creator><creator>Yuan, Q.</creator><creator>Yu, Y.‐Y.</creator><creator>Xia, N.‐S.</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>201702</creationdate><title>Baseline hepatitis B core antibody predicts treatment response in chronic hepatitis B patients receiving long‐term entecavir</title><author>Xu, J.‐H. ; Song, L.‐W. ; Li, N. ; Wang, S. ; Zeng, Z. ; Si, C.‐W. ; Li, J. ; Mao, Q. ; Zhang, D.‐Z. ; Tang, H. ; Sheng, J.‐F. ; Chen, X.‐Y. ; Ning, Q. ; Shi, G.‐F. ; Xie, Q. ; Yuan, Q. ; Yu, Y.‐Y. ; Xia, N.‐S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3816-73a3cb3a144a25482a94e7658910fadb7d430cc54c17f4fffd334cfd5ec0820b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adult</topic><topic>Antiviral agents</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Antiviral drugs</topic><topic>China</topic><topic>entecavir</topic><topic>Female</topic><topic>Guanine - analogs & derivatives</topic><topic>Guanine - therapeutic use</topic><topic>Health risk assessment</topic><topic>Hepatitis</topic><topic>Hepatitis B Antibodies - blood</topic><topic>hepatitis B core antibody</topic><topic>Hepatitis B e antigen</topic><topic>Hepatitis B e Antigens - blood</topic><topic>Hepatitis B, Chronic - drug therapy</topic><topic>Hepatitis B, Chronic - immunology</topic><topic>Humans</topic><topic>Interferon</topic><topic>Male</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>Seroconversion</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Xu, J.‐H.</creatorcontrib><creatorcontrib>Song, L.‐W.</creatorcontrib><creatorcontrib>Li, N.</creatorcontrib><creatorcontrib>Wang, S.</creatorcontrib><creatorcontrib>Zeng, Z.</creatorcontrib><creatorcontrib>Si, C.‐W.</creatorcontrib><creatorcontrib>Li, J.</creatorcontrib><creatorcontrib>Mao, Q.</creatorcontrib><creatorcontrib>Zhang, D.‐Z.</creatorcontrib><creatorcontrib>Tang, H.</creatorcontrib><creatorcontrib>Sheng, J.‐F.</creatorcontrib><creatorcontrib>Chen, X.‐Y.</creatorcontrib><creatorcontrib>Ning, Q.</creatorcontrib><creatorcontrib>Shi, G.‐F.</creatorcontrib><creatorcontrib>Xie, Q.</creatorcontrib><creatorcontrib>Yuan, Q.</creatorcontrib><creatorcontrib>Yu, Y.‐Y.</creatorcontrib><creatorcontrib>Xia, N.‐S.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of viral hepatitis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Xu, J.‐H.</au><au>Song, L.‐W.</au><au>Li, N.</au><au>Wang, S.</au><au>Zeng, Z.</au><au>Si, C.‐W.</au><au>Li, J.</au><au>Mao, Q.</au><au>Zhang, D.‐Z.</au><au>Tang, H.</au><au>Sheng, J.‐F.</au><au>Chen, X.‐Y.</au><au>Ning, Q.</au><au>Shi, G.‐F.</au><au>Xie, Q.</au><au>Yuan, Q.</au><au>Yu, Y.‐Y.</au><au>Xia, N.‐S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Baseline hepatitis B core antibody predicts treatment response in chronic hepatitis B patients receiving long‐term entecavir</atitle><jtitle>Journal of viral hepatitis</jtitle><addtitle>J Viral Hepat</addtitle><date>2017-02</date><risdate>2017</risdate><volume>24</volume><issue>2</issue><spage>148</spage><epage>154</epage><pages>148-154</pages><issn>1352-0504</issn><eissn>1365-2893</eissn><abstract>Summary
Studies regarding the clinical significance of quantitative hepatitis B core antibody (anti‐HBc) in patients with chronic hepatitis B receiving first‐line nucleos(t)ide analogues is limited. The aim of this study was to determine the performance of anti‐HBc as a predictor for hepatitis B e antigen (HBeAg) seroconversion in HBeAg‐positive CHB patients treated with entecavir. This was a retrospective cohort study consisting of 139 Chinese patients enrolled in a multicenter clinical trial treated with entecavir or entecavir maleate for up to 240 weeks. Anti‐HBc evaluation was conducted for all the available samples using a newly developed double‐sandwich anti‐HBc immunoassay. At week 240, 35 (25.2%) patients achieved a serological response (HBeAg seroconversion) and these patients at week 240 had significantly higher levels of anti‐HBc (P<.01). We defined 4.65 log10 IU·mL−1, with a maximum sum of sensitivity and specificity, as the optimal cut‐off value of baseline anti‐HBc level to predict seroconversion. Patients with baseline anti‐HBc ≥4.65 log10 IU·mL−1 had 28.0% (26/93) and 35.5% (33/93) chance of seroconversion at weeks 144 and 240, respectively. The baseline anti‐HBc level was the strongest predictor for seroconversion at week 144 (OR: 5.78, 95% confidence interval [CI]: 2.05‐16.34, P=.001). The baseline anti‐HBc level was a strong predictor for seroconversion at week 240 (OR: 5.36, 95% CI: 2.17‐13.25, P<.001). Hence, baseline anti‐HBc titre is a useful predictor of long‐term entecavir therapy efficacy in HBeAg‐positive CHB patients, which could be used to optimize antiviral therapy.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>27891715</pmid><doi>10.1111/jvh.12626</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1352-0504 |
| ispartof | Journal of viral hepatitis, 2017-02, Vol.24 (2), p.148-154 |
| issn | 1352-0504 1365-2893 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1844355101 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adult Antiviral agents Antiviral Agents - therapeutic use Antiviral drugs China entecavir Female Guanine - analogs & derivatives Guanine - therapeutic use Health risk assessment Hepatitis Hepatitis B Antibodies - blood hepatitis B core antibody Hepatitis B e antigen Hepatitis B e Antigens - blood Hepatitis B, Chronic - drug therapy Hepatitis B, Chronic - immunology Humans Interferon Male Patients Prognosis Retrospective Studies Seroconversion Treatment Outcome |
| title | Baseline hepatitis B core antibody predicts treatment response in chronic hepatitis B patients receiving long‐term entecavir |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T06%3A55%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Baseline%20hepatitis%20B%20core%20antibody%20predicts%20treatment%20response%20in%20chronic%20hepatitis%20B%20patients%20receiving%20long%E2%80%90term%20entecavir&rft.jtitle=Journal%20of%20viral%20hepatitis&rft.au=Xu,%20J.%E2%80%90H.&rft.date=2017-02&rft.volume=24&rft.issue=2&rft.spage=148&rft.epage=154&rft.pages=148-154&rft.issn=1352-0504&rft.eissn=1365-2893&rft_id=info:doi/10.1111/jvh.12626&rft_dat=%3Cproquest_cross%3E1928256185%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1858615558&rft_id=info:pmid/27891715&rfr_iscdi=true |